GlassScriptPhysician profile
Robin Whitman
NPI 1740205707
$4,492.77
in general payments reported to CMS, 2019-2025
33 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $1,308 · 2023: $1,720 · 2024: $876 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $594.23 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $425.82 | 2021-2024 | Verquvo |
| Pfizer INC. | $388.82 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $277.62 | 2021-2024 | Farxiga, Brilinta |
| Amgen INC. | $265.67 | 2021-2024 | Repatha |
| Medtronic, INC. | $239.65 | 2021-2024 | Linq II, Mycarelink |
| Esperion Therapeutics, INC. | $233.37 | 2021-2024 | Nexletol |
| Cvrx, INC. | $221.38 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $197.61 | 2021-2024 | Xarelto |
| Abbott Laboratories | $192.47 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $192.02 | 2021-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.42 | 2021-2024 | Lifevest |
| Biosense Webster, INC. | $135.05 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $133.04 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.47 | 2022-2024 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $67.12 | 2022-2023 | Amvuttra |
| Amarin Pharma, INC. | $66.84 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $66.76 | 2024 | Arcalyst |
| Novo Nordisk INC | $57.22 | 2022-2024 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $53.84 | 2023 | Injectafer |
| Boston Scientific Corporation | $47.76 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $41.64 | 2021 | |
| Irhythm Technologies, INC. | $41.06 | 2021-2023 | Zio Xt Patch |
| Abiomed | $40.54 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $36.90 | 2021 | |
| Heartflow, INC. | $36.77 | 2024 | |
| Tactile Systems Technology INC | $26.31 | 2025 | Flexitouch Plus, Nimbl |
| Kestra Medical Technology Services, INC. | $25.90 | 2024 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $22.91 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $19.76 | 2023 | |
| Chiesi USA, INC. | $19.33 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.45 | 2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Whitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.